Episode 69: The future of AbbVieGan, the dogma of amyloid, & some questionable biotech marketing episode artwork

EPISODE · Jun 27, 2019 · 25 MIN

Episode 69: The future of AbbVieGan, the dogma of amyloid, & some questionable biotech marketing

from The Readout Loud · host STAT

Can Botox make Big Pharma attractive? What qualifies as a "cabal"? And will the CRISPR patent fight outlive us all?

Episode metadata supplied by the publisher feed · Published Jun 27, 2019

Embed this episode

Ready to play

Episode 69: The future of AbbVieGan, the dogma of amyloid, & some questionable biotech marketing

0:00 25:31

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Readout Loud?

This episode is 25 minutes long.

When was this The Readout Loud episode published?

This episode was published on June 27, 2019.

Can I download this The Readout Loud episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!